To evaluate whether the presence of CD86+ CLL cells impacts on the course of disease, we measured CD86 levels in a set of 59 previously untreated CLL patients (Supporting Information Table 1) and correlated the size of the CD86 fraction in the peripheral blood with time to first treatment. Here, CD86 is linked to B-cell chronic lymphocytic leukemia.